Drug Profile
PRX ASL
Alternative Names: PRXASLLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator PhaseRx
- Class
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Argininosuccinic aciduria
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Argininosuccinic aciduria in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Argininosuccinic aciduria in USA
- 28 Nov 2017 The European Medicines Agency's Committee for Orphan Medicinal Products recommends orphan drug designation for PRX-ASL in European Union for Argininosuccinic aciduria (argininosuccinate lyase deficiency)